New treatments for metastic prostate cancer.
The FDA has approved 2 new treatments for castration-resistant (formerly called hormone-refractory) prostate cancer. Sipuleucel-T (Provenge - Dendreon) s the first immunotherapy approved for treatment of prostate cancer. Cabazitaxel (Jevtana - Sanofi-Aventis) is approved for second-line treatment of metastatic castration-resistant prostate cancer previously treated with docetaxel (Taxotere).